Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

被引：8
|
作者：
Kittai, Adam S. [1 ,4 ]
Best, Scott [1 ]
Thurlow, Bria [1 ]
Lam, Vi [1 ]
Hashiguchi, Taylor [1 ]
Goodyear, Shaun [1 ]
Persky, Daniel O. [2 ]
Okada, Craig [1 ]
Park, Byung [1 ]
Spurgeon, Stephen E. [1 ]
Danilov, Alexey V. [1 ,3 ]
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA
[2] Univ Arizona, Ctr Canc, Tucson, AZ USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA
[4] Ohio State Univ, Columbus, OH 43210 USA
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 07期
关键词：
INHIBITION; SYK; IBRUTINIB; GS-9973; MCL-1;
D O I：
10.3324/haematol.2020.270298
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In recent years, the utilization of CS-MWCNT as targeted drug carriers has attracted considerable attention. Hericium erinaceus polysaccharide (HEP) has been reported as an immunostimulant to improve immune responses. This study was focussed on developing CS-MWCNT encapsulating HEP (CS-MWCNT-HEP). Using in mice peritoneal macrophages, we found the immune response could be effectively regulated by CS-MWCNT-HEP, promoted the expression of the MHCII, CD86, F4/80 and gp38. Moreover, the mice immunized with CS-MWCNT-HEP nanoparticles significantly extended PCV2-specific IgG immune response and the levels of cytokines. The results demonstrated that CS-MWCNT-HEP may be a promising drug delivery system for immuno-enhancement. (c) 2021 Elsevier B.V. All rights reserved.
引用
收藏
页码：2022 / 2025
页数：4
相关论文
共 50 条
  • [1] SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL)
    Kittai, Adam S.
    Best, Scott R.
    Thurlow, Bria
    Gokcora, Basak
    Stadnik, Andrzej
    MacKinnon, Renee
    Rowland, Taylor Hashiguchi
    Persky, Daniel O.
    Park, Byung
    Spurgeon, Stephen E.
    Danilov, Alexey
    BLOOD, 2019, 134
  • [2] A phase I/II study of the SYK inhibitor entospletinib in combination with obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)
    Kittai, Adam
    Hashiguchi, Taylor
    Thurlow, Bria
    Gokcora, Basak
    Stadnik, Andrzej
    MacKinnon, Renee
    Stephen, Monette
    Moore, Lacey
    Persky, Daniel
    Park, Byung
    Spurgeon, Stephen
    Danilov, Alexey
    LEUKEMIA & LYMPHOMA, 2020, 61 : 76 - 77
  • [3] Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study
    Awan, Farrukh T.
    Thirman, Michael J.
    Patel-Donnelly, Dipti
    Assouline, Sarit
    Rao, Arati, V
    Ye, Wei
    Hill, Brian
    Sharman, Jeff P.
    LEUKEMIA & LYMPHOMA, 2019, 60 (08) : 1972 - 1977
  • [4] Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
    Kutsch, Nadine
    Pallasch, Christian
    Tausch, Eugen
    Boehme, Volkmar
    Ritgen, Matthias
    Liersch, Ruediger
    Wacker, Alexander
    Jacobs, Georg
    Trappe, Ralf Ulrich
    Dreger, Peter
    Fischer, Kirsten
    Fink, Anna-Maria
    Stilgenbauer, Stephan
    Zhai, Shuyan
    Li, Biao
    Jurgensmeier, Juliane M.
    Rajakumaraswamy, Nishanthan
    Bhargava, Pankaj
    Hallek, Michael
    Eichhorst, Barbara F.
    HEMASPHERE, 2022, 6 (04):
  • [5] Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia
    Elter, Thomas
    Kilp, Julia
    Borchmann, Peter
    Schulz, Holger
    Hallek, Michael
    Engert, Andreas
    Haematologica-The Hematology Journal, 2009, 94 (01): : 150 - 152
  • [6] BENDAMUSTINE MONOTHERAPY IN ELDERLY PATIENTS AFFECTED BY RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
    Lucania, A.
    Esposito, M.
    Della Cioppa, P.
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2015, 100 : 74 - 74
  • [7] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Ryan, Christine E.
    Brander, Danielle M.
    Barr, Paul M.
    Tyekucheva, Svitlana
    Hackett, Liam R.
    Collins, Mary C.
    Fernandes, Stacey M.
    Ren, Yue
    Zhou, Yinglu
    McDonough, Mikaela M.
    Walker, Heather A.
    McEwan, Monica R.
    Abramson, Jeremy S.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    LEUKEMIA, 2023, 37 (04) : 835 - 842
  • [8] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Christine E. Ryan
    Danielle M. Brander
    Paul M. Barr
    Svitlana Tyekucheva
    Liam R. Hackett
    Mary C. Collins
    Stacey M. Fernandes
    Yue Ren
    Yinglu Zhou
    Mikaela M. McDonough
    Heather A. Walker
    Monica R. McEwan
    Jeremy S. Abramson
    Eric D. Jacobsen
    Ann S. LaCasce
    David C. Fisher
    Jennifer R. Brown
    Matthew S. Davids
    Leukemia, 2023, 37 : 835 - 842
  • [9] Exposure-Response of Entospletinib (ENTO) for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
    Gupta, Sneha
    Meng, Amy
    Sharma, Shringi
    Ye, Wei
    Silverman, Jeffrey
    Abella, Esteban M.
    Mathias, Anita
    BLOOD, 2017, 130
  • [10] Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib
    Sharman, Jeff
    Di Paolo, Julie
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (03) : 157 - 170
12345